Heart failure & cardiomyopathies

Long-Term Cost-Effectiveness of Transcatheter Mitral Valve Repair in HF Patients with Secondary Mitral Regurgitation

ESC Heart FailPublished Cost-effectiveness analysis

Authors' conclusion

MitraClip + guideline-directed medical therapy was cost-effective in heart failure patients with secondary mitral regurgitation in the United Kingdom, Germany, and the United States, but not in mainland China from the perspective of the national healthcare system.

Study context

Population
HF patients with secondary mitral regurgitation; healthcare systems of mainland China, UK, Germany and US; base case mean age 72.2 yearsmodel base case
Comparison
MitraClip + GDMT vs GDMT alone
Outcome
Lifetime incremental cost-effectiveness ratio
Follow-up
Lifetime horizon
Methodological detailsdecision + Markov model, two-stage (decision + Markov) model, lifetime horizon, based on 5-year COAPT trial follow-up, probabilistic sensitivity analysis, Health utilities from 5-year COAPT trial follow-up; direct healthcare costs from nationally representative data; future utilities and costs discounted at country-specific rates
  • Decision + Markov model
  • Two-stage (decision + Markov) model
  • Lifetime horizon
  • Based on 5-year COAPT trial follow-up
  • Probabilistic sensitivity analysis
  • Health utilities from 5-year COAPT trial follow-up; direct healthcare costs from nationally representative data; future utilities and costs discounted at country-specific rates

Main finding

As reported in the abstract

Incremental QALYs and ICER, MitraClip + GDMT vs GDMT

Mainland China: incremental QALY gain 0.71; ICER per QALY

¥468 462

UK: incremental QALY gain 0.76; ICER per QALY

£28 910

Germany: incremental QALY gain 0.78; ICER per QALY

€26 045

US: incremental QALY gain 0.78; ICER per QALY

$71 199

Further findings

HF re-hospitalizations · lifetime horizon

Fewer HF re-hospitalizations per 1000 treated patients with MitraClip
829

Probabilistic sensitivity analysis: proportion cost-effective at country-specific willingness-to-pay thresholds

Mainland China
0.2%
UK
59.4%
Germany
99.6%
US
84.7%

Original publication

Long-Term Cost-Effectiveness of Transcatheter Mitral Valve Repair in HF Patients with Secondary Mitral Regurgitation. ESC Heart Fail. Published 22 March 2024. doi:10.1002/ehf2.14729

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.